Abstract
microRNAs (miRNAs) are of great significance in cancer treatment, which may have a desirable result on the regulation of tumorigenesis, progression, recurrence, and chemo-resistance of ovarian cancer. However, the research on the further potential application of miR-4461 in ovarian cancer is little and limited. Therefore, the study in this paper focus on the investigation of the of miR-4461 in ovarian cancer progression and chemo-resistance. The phenomenon that the proliferation and metastasis of ovarian cancer cells can be promoted by miR4461 is revealed in functional assays. Through the bioinformatics and luciferase reporter analysis, the PTEN is validated to be the direct target of miR-4461 in ovarian. The association between the expression of miR-4461 and PTEN is negative in in human ovarian cancer tissues. The distinction of growth and metastasis capacity between miR-4461 knockdown ovarian cancer cells and control cells is partially abolished by si-PTEN. Moreover, it was found that cisplatin treatment has obvious effect on the miR-4461 knockdown ovarian cancer cells. In summary, the data given in this paper indicate that the miR-4461 can be regarded as a potential onco-miRNA in ovarian cancer by targeting PTEN.
Highlights
Ovarian cancer (OC) has been one of the most global malignant tumors among the women [1]
The results showed that miR-4461 levels were upregulated in OC tissues compared with normal tissues miR-4461 Drives OC Cells Progression (Figure 1A)
The results showed that miR-4461 knockdown did not affect the growth, viability and survival of ovarian surface epithelial cells (OSE) cells (Supplementary Figures 1B,C)
Summary
Ovarian cancer (OC) has been one of the most global malignant tumors among the women [1]. The tendency of the incidence of the OC in the US is descend. On the contrary, it is rising in China [2]. OC patients do not usually experience noticeable symptoms in the early stage of tumorigenesis and until now, there is no efficacious method which has been found for the early detection and treatment of OC. Most OC patients have not been diagnosed with ovarian cancer until advanced stage, and they miss the best opportunity for treatment [3, 4]. More than 70% advanced OC patients will recur after surgery [5]. It’s pressing to explore the potential mechanism of OC and uncover new treatment target to improve the prognosis of OC patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
